RICHMOND, Va.--(BUSINESS WIRE)--Commonwealth Biotechnologies, Inc. (“CBI”) (NASDAQ Capital Market: CBTE) is pleased to provide an update regarding Venturepharm (Asia), CBI’s joint venture with Venturepharm Laboratories Ltd (“VPL”) (HKEX: 8225.HK). The joint venture was established to leverage CBI’s and VPL’s respective strengths in drug discovery and clinical research and development. This is the first of four facilities now planned for the company’s expansion into China.
